(Q33959115)

30 July 2017

1 reference

title

Exemestane: a review of its use in postmenopausal women with advanced breast cancer (English)

1 reference

30 July 2017

1 reference

ChEBI release 2020-05-28

D Clemett

1

1 reference

30 July 2017

H M Lamb

series ordinal

2

1 reference

30 July 2017

language of work or name

1 reference

1 June 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

59

1 reference

30 July 2017

issue

6

1 reference

30 July 2017

page(s)

1279-1296

1 reference

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

30 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059060-00007

High-dose intravenous pamidronate for metastatic bone pain

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059060-00007

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

21 January 2018

1 reference

12 December 2020

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

1 reference

12 December 2020

Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study

1 reference

12 December 2020

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

12 December 2020

Aromatase inhibitors in the treatment of postmenopausal breast cancer

1 reference

12 December 2020

Comprehensive pharmacology and clinical efficacy of aromatase inhibitors

1 reference

12 December 2020

Update on endocrine therapy for breast cancer

1 reference

12 December 2020

Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.

1 reference

12 December 2020

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women

1 reference

12 December 2020

Update: NCCN practice guidelines for the treatment of breast cancer. National Comprehensive Cancer Network

1 reference

12 December 2020

Aromatase inhibitors in the treatment of advanced breast cancer

1 reference

12 December 2020

Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone

1 reference

12 December 2020

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

12 December 2020

Endocrine treatment for breast cancers: biological rationale and current progress

1 reference

12 December 2020

Risks and benefits of aromatase inhibitors in postmenopausal breast cancer

1 reference

12 December 2020

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

12 December 2020

Role of aromatase inhibitors in advanced breast cancer

1 reference

12 December 2020

Novel aromatase and 5 alpha-reductase inhibitors

1 reference

12 December 2020

Biology of aromatase inhibitors: pharmacology/endocrinology within the breast

1 reference

12 December 2020

Cancer of the breast: the past decade (second of two parts)

1 reference

12 December 2020

The therapeutic potential of novel aromatase inhibitors in breast cancer

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

12 December 2020

Current perspectives on aromatase inhibitors in breast cancer

1 reference

12 December 2020

Treatment of breast cancer

1 reference

12 December 2020

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

1 reference

12 December 2020

Adjuvant systemic therapy for women with node-negative breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer

1 reference

12 December 2020

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

1 reference

12 December 2020

Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer

1 reference

12 December 2020

Aromatase inhibitors and their future role in post-menopausal women with early breast cancer

1 reference

12 December 2020

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

12 December 2020

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

1 reference

12 December 2020

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

12 December 2020

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group

1 reference

12 December 2020

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

12 December 2020

10.2165/00003495-200059060-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1012642574

0 references

1 reference